Devin E. Turner, Ph.D., Founder and CEO
Devin Turner is the founder of Abveris Antibody and creator of DiversimAbTM and BinderGenTM antibody discovery technologies. In six years without investment, Devin led Abveris through substantial growth, technological innovation, a successful exit and fulfilling its mission to deliver scores of biotherapeutic lead molecules to drug hunters. More recently, Devin was the Head of Antibody Discovery Services at Alloy Therapeutics, where he led a world-class multidisciplinary team generating fully human antibody-based therapeutics from Alloy’s state-of-the-art suite of humanized mice. Devin continues his passion for immunotherapeutics through his latest company, Immunovive, a Boston-based CRO accelerating biologics discovery with its robust in vivo-based antibody hit generation platform, BinderGenTM, delivering diverse panels of high affinity monoclonal hybridomas in just 6 weeks. When not immersed in science, Devin enjoys BBQing, hiking, biking, boating, and being the best dad ever. Devin earned his B.S. in Molecular, Cellular, and Developmental Biology from UCLA and his Ph.D. in Immunology from Harvard Medical School.
Rashed Abdullah, Ph.D., PMP, Associate Director of Operations and Business Development
Dr. Rashed Abdullah is a seasoned scientist with over two decades of experience in therapeutic antibody discovery, oncology, vaccine development, and neurodegenerative disease research. A certified Project Management Professional (PMP), he has led R&D programs and cross-functional teams across biotech and CRO environments. His expertise spans monoclonal and polyclonal antibody development, AOC/ADC platforms, assay design, and preclinical strategy. Dr. Abdullah has held leadership roles at Gennao Bio, Abveris (now Twist Bio), and Immunovive LLC, where he currently serves as Associate Director of Operations and Business Development. He holds a Ph.D. in Biology from St. John's University and has contributed to numerous peer-reviewed publications in the field of therapeutic discovery.
Tom Daly, Jr., M.Sc., Scientist
Tom has over 17 years combined experience in drug discovery, particularly using in vivo models in disease areas of cancer and autoimmune diseases. Throughout his career he has dedicated his efforts to discover and develop drug therapies such as Necuparanib, which reached Phase II; CTX-471, currently in Phase I clinical trials; and others that are still in preclinical stage development. He was also on the initial development team for Nipoclamib, an anti-FcRn approved by the FDA in April 2025. Tom has developed tumor, platelet depletion, and rescue in vivo models, as well as other pharmacokinetic models. Most recently at Alloy Therapeutics and now here at Immunovive, he has specialized in the generation of monoclonal hybridoma colonies from mouse B cells that generate target specific antibodies for customer projects and is dedicated to the delivery of a potential drug target for clients. He earned his Masters Degree in Biotechnology from Worcester State University.
